CDER Office Of Biotech Products To Oversee Biologics Quality After Transition
Executive Summary
Center for Drug Evaluation & Research Office of New Drug Chemistry Director Yuan-yuan Chiu, PhD, will serve as acting director of FDA's Office of Biotech Products when the office is officially established in October
You may also be interested in...
FDA Biotech Products Office Acting Director Is CBER Veteran Webber
FDA Office of Biotechnology Products Acting Director Keith Webber, PhD, will bring a CBER perspective to the office's quality review functions
FDA Biotech Products Office Acting Director Is CBER Veteran Webber
FDA Office of Biotechnology Products Acting Director Keith Webber, PhD, will bring a CBER perspective to the office's quality review functions
CBER/CDER Consolidation: 20 Staff Vacancies, Two ODE VI Clinical Divisions
FDA is actively recruiting to replace 20 staffers who have left the Center for Biologics Evaluation & Research since plans to consolidate with CDER were announced a year ago